UNSPSC 51262303: Viloxazine

This classification denotes an adrenergic uptake inhibitor and second-generation antidepressive agent with the molecular formula C13H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5I5Y2789ZF, chemically known as 2-(2-ethoxyphenoxymethyl)tetrahydro-1,4-oxazine but generally known as viloxazine, which bears US NIH Compound Identifier 5666. European Medicines Agency schedules Viloxazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00049MIG.

UNSPSC 51262303 Viloxazine is a Commodity code identifying a specific pharmaceutical product, but the recent state and local solicitations tagged under it do not align with viloxazine procurement. The most recent opportunities reflect naloxone and drug deactivation systems acquisition on one hand, and exploratory vendor research for direct-to-manufacturer prescription programs on the other — neither of which involves viloxazine as a named purchase item. State and local governments appear to show little relevant recent activity specifically for viloxazine under this code.

The mismatch between the code's nominal scope and actual recent solicitation content suggests either tagging inconsistency in the source data or that viloxazine procurement, if it occurs at state and local levels, is not currently visible in posted notices. Seminole County, Florida issued an IFB (No. IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems with quarterly deliveries to its Community Health Building, while the Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) to gather vendor intelligence on direct-to-manufacturer pharmacy prescription fulfillment — both acquisitions unrelated to viloxazine. Without additional solicitations demonstrating active viloxazine procurement at the state or local level, this code does not present a clear opportunity profile for business development targeting.